Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InfuSystem Holdings, Inc. filings document financial reporting, governance and material-event disclosures for a health care service provider focused on outpatient durable medical equipment services. Recent 8-K filings furnish earnings releases, conference-call announcements, investor presentations and Regulation FD disclosures tied to Patient Services and Device Solutions.
The company’s proxy materials cover board matters, shareholder voting, executive compensation and equity award disclosures. Other filings document accounting oversight, including changes in the independent registered public accounting firm, audits of consolidated financial statements and internal control over financial reporting.
InfuSystem Holdings director Paul Andrew Gendron received a new stock option grant as part of his compensation. He was granted options to acquire 24,890 shares of common stock at an exercise price of $8.37 per share, expiring in 2036. These options vest on May 12, 2027. Following the reported transactions, he directly holds 70,000 shares of InfuSystem common stock, indicating this filing reflects equity-based incentives rather than open-market buying or selling.
InfuSystem Holdings Executive VP and CFO Barry G. Steele reported new equity awards. He received 17,121 restricted stock units that convert into common stock on a one-for-one basis and 35,668 stock options with an exercise price of $8.37 per share. The options vest in four equal annual installments beginning on May 12, 2027, while the RSUs vest in three equal annual installments starting the same date. After these awards, he directly holds 96,590 shares of common stock.
InfuSystem Holdings President and CEO Carrie Lachance reported new equity awards and updated holdings. She received a grant of 29,816 restricted stock units, which convert into common stock on a one-for-one basis and vest in three equal annual installments beginning on May 12, 2027. She also received a stock option covering 62,117 shares of common stock at an exercise price of $8.37 per share, expiring on May 12, 2036, vesting in four equal annual installments starting May 12, 2027. Following these awards, she directly holds 238,123 shares of InfuSystem common stock. These actions reflect compensation-related grants rather than open-market purchases or sales.
InfuSystem Holdings, Inc executive Jerod Funke, EVP–Chief HR Officer, reported new equity compensation awards. He received 11,478 restricted stock units, which each convert into one share of common stock and vest in three equal annual installments beginning on May 12, 2027.
He was also granted a stock option for 23,913 shares of common stock at an exercise price of $8.37 per share, vesting in four equal annual installments beginning May 12, 2027 and expiring on May 12, 2036. Following these awards, he holds 18,662 shares of common stock directly, alongside the new unvested RSUs and options.
InfuSystem Holdings director Kenneth D. Eichenbaum reported a new stock option grant tied to the company’s common stock. He received options covering 24,890 shares at an exercise price of $8.37 per share, recorded as a grant or award acquisition.
The option vests on May 12, 2027 and expires on May 12, 2036, giving him the right to buy InfuSystem common shares at the fixed exercise price once vested. Following these entries, he is shown holding 6,000 shares of common stock directly.
InfuSystem Holdings, Inc. reported a board leadership change following its 2026 Annual Meeting of Stockholders held on May 11, 2026. The newly constituted Board of Directors elected Beverly Huss to serve as Chairman of the Board of Directors.
The company states that there are no arrangements or understandings with other persons related to her appointment, no family relationships between Ms. Huss and any directors or executive officers, and no material related-party transactions involving her that require disclosure under Item 404(a) of Regulation S-K.
InfuSystem Holdings, Inc. reported results from its 2026 annual stockholder meeting and an update to its equity compensation plan. Stockholders approved a Third Amendment to the 2021 Equity Incentive Plan, increasing the maximum number of shares of common stock reserved for issuance under the plan to 7,000,000 shares. The plan allows a range of equity and cash awards for employees, consultants, and directors, administered by the Board’s Compensation Committee.
All seven Board nominees were elected, each receiving over 11.8 million votes in favor with 3.7 million broker non-votes. On a non-binding, advisory basis, stockholders approved executive compensation with about 11.9 million votes for and 1.1 million against. They also approved the equity plan amendment and ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
InfuSystem Holdings director Paul Andrew Gendron bought additional company stock in the open market. On this Form 4, he reports purchasing 5,000 shares of common stock in an open-market transaction at a weighted average price of $8.88 per share, increasing his direct holdings to 70,000 shares. A footnote explains the price reflects multiple trades on the transaction date and that full trade-by-trade pricing information is available upon request.
InfuSystem Holdings, Inc. President and CEO Carrie Lachance bought a net 3,000 shares of common stock in open-market purchases. She acquired 2,000 shares at $8.83 per share on May 8, 2026 and 1,000 shares at $8.46 per share on May 11, 2026.
After these transactions, she directly holds 238,123 shares of InfuSystem common stock. This total includes an additional 2,949 shares recently acquired through the company’s Employee Stock Purchase Plan.
InfuSystem Holdings, Inc. Executive VP and CFO Barry G. Steele reported buying 7,000 shares of common stock in an open-market purchase at a weighted average price of $8.707 per share. Following this transaction, he directly holds 96,590 common shares, including 1,590 shares recently acquired through the Company’s Employee Stock Purchase Plan.